The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

The U.S. Advanced Wound Care market has demonstrated strong growth, with its valuation at $3.35 billion in 2019, and projections suggest it will reach $4.97 billion by 2027. This ...

Innovative polylactic acid (PLA)-curcumin nanofibers enhanced with carbon nanotubes (CNTs) improve antibacterial activity, ...

Introduction Burn care refers to the medical management and treatment of heat injuries, which can range from minor superficial burns to severe, ...